Abstract | BACKGROUND: METHODS: This study was conducted at three university hospitals between January 2013 and August 2015. Hospitalized adult patients presenting with fever were screened for healthcare-associated urinary tract infection (HA-UTI). When ESBL-EC was solely detected and susceptible to a randomized antibiotic in vitro, the case was included in the final analysis. Participants were treated for 10-14 days with PTZ, cefepime, or ertapenem. RESULTS: A total of 66 participants were evenly assigned to the PTZ and ertapenem treatment groups. After the recruitment of six participants, assignment to the cefepime treatment group was stopped because of an unexpectedly high treatment failure rate. The baseline characteristics of these participants did not differ from participants in other treatment groups. The clinical and microbiological response to PTZ treatment was estimated to be 94% and was similar to the response to ertapenem treatment. The efficacy of cefepime was 33.3%. In the cefepime group, age, Charlson comorbidity index, genotype, and minimal inhibitory concentration (MIC) did not significantly affect the success of treatment. Similarly, genotype seemed to be irrelevant with respect to clinical outcome in the PTZ group. Expired cases tended to involve septic shock with a high Charlson comorbidity index and high MIC. CONCLUSION: Results from this study suggest that PTZ is effective in the treatment of urinary tract infection caused by ESBL-EC when the in vitro test indicates susceptibility. In addition, cefepime should not be used as an alternative treatment for urinary tract infection caused by ESBL-EC. TRIAL REGISTRATION: The trial was registered with the Clinical Research Information Service of Korea Centers for Disease Control and Prevention. (KCT0001895).
|
Authors | Yu Bin Seo, Jacob Lee, Young Keun Kim, Seung Soon Lee, Jeong-A Lee, Hyo Youl Kim, Young Uh, Han-Sung Kim, Wonkeun Song |
Journal | BMC infectious diseases
(BMC Infect Dis)
Vol. 17
Issue 1
Pg. 404
(06 07 2017)
ISSN: 1471-2334 [Electronic] England |
PMID | 28592240
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Bacterial Agents
- Cephalosporins
- beta-Lactamase Inhibitors
- beta-Lactams
- Piperacillin, Tazobactam Drug Combination
- Cefepime
- Penicillanic Acid
- beta-Lactamases
- Ertapenem
- Tazobactam
- Piperacillin
|
Topics |
- Aged
- Aged, 80 and over
- Anti-Bacterial Agents
(therapeutic use)
- Cefepime
- Cephalosporins
(therapeutic use)
- Cross Infection
- Ertapenem
- Escherichia coli
(drug effects, enzymology, genetics, isolation & purification)
- Escherichia coli Infections
(drug therapy, microbiology)
- Female
- Genotype
- Humans
- Male
- Middle Aged
- Penicillanic Acid
(analogs & derivatives, therapeutic use)
- Piperacillin
(therapeutic use)
- Piperacillin, Tazobactam Drug Combination
- Prospective Studies
- Republic of Korea
- Tazobactam
- Urinary Tract Infections
(drug therapy, microbiology)
- beta-Lactamase Inhibitors
(therapeutic use)
- beta-Lactamases
(genetics)
- beta-Lactams
(therapeutic use)
|